168 related articles for article (PubMed ID: 38321333)
1. Impact of vortioxetine on psychosocial functioning moderated by symptoms of fatigue in post-COVID-19 condition: a secondary analysis.
Badulescu S; Le GH; Wong S; Kwan ATH; Guo Z; Teopiz KM; Phan L; Subramaniapillai M; Rosenblat JD; Mansur RB; McIntyre RS
Neurol Sci; 2024 Apr; 45(4):1335-1342. PubMed ID: 38321333
[TBL] [Abstract][Full Text] [Related]
2. Association between fatigue and depressive symptoms in persons with post-COVID-19 condition: a post hoc analysis.
Teopiz KM; Kwan ATH; Le GH; Guo Z; Badulescu S; Ceban F; Meshkat S; Di Vincenzo JD; d'Andrea G; Cao B; Ho R; Rhee TG; Dev DA; Phan L; Subramaniapillai M; Mansur RB; Rosenblat JD; McIntyre RS
Curr Med Res Opin; 2024 Jul; 40(7):1203-1209. PubMed ID: 38860901
[TBL] [Abstract][Full Text] [Related]
3. Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial.
McIntyre RS; Phan L; Kwan ATH; Mansur RB; Rosenblat JD; Guo Z; Le GH; Lui LMW; Teopiz KM; Ceban F; Lee Y; Bailey J; Ramachandra R; Di Vincenzo J; Badulescu S; Gill H; Drzadzewski P; Subramaniapillai M
Brain; 2024 Mar; 147(3):849-857. PubMed ID: 37936330
[TBL] [Abstract][Full Text] [Related]
4. Assessing the Effects of Metabolic Disruption, Body Mass Index and Inflammation on Depressive Symptoms in Post-COVID-19 Condition: A Randomized Controlled Trial on Vortioxetine.
Kwan ATH; Guo Z; Ceban F; Le GH; Wong S; Teopiz KM; Rhee TG; Ho R; Di Vincenzo JD; Badulescu S; Meshkat S; Cao B; Rosenblat JD; d'Andrea G; Dev DA; Phan L; Subramaniapillai M; McIntyre RS
Adv Ther; 2024 May; 41(5):1983-1994. PubMed ID: 38520501
[TBL] [Abstract][Full Text] [Related]
5. Impact of vortioxetine on depressive symptoms moderated by symptoms of anxiety in persons with post-COVID-19 condition: A secondary analysis.
Le GH; Kwan ATH; Guo Z; Teopiz KM; Wong S; Meshkat S; d'Andrea G; Ho R; Rhee TG; Cao B; Badulescu S; Phan L; Rosenblat JD; Mansur RB; Subramaniapillai M; McIntyre RS
Psychiatry Res; 2024 Jun; 339():116068. PubMed ID: 38954891
[TBL] [Abstract][Full Text] [Related]
6. Relationship between anhedonia and psychosocial functioning in post-COVID-19 condition: a
Liao S; Teopiz KM; Kwan ATH; Le GH; Wong S; Ballum H; Rhee TG; Badulescu S; Cao B; Guo Z; Meshkat S; Phan L; Subramaniapillai M; Ho R; McIntyre RS
Curr Med Res Opin; 2024 Jul; ():1-5. PubMed ID: 38954402
[TBL] [Abstract][Full Text] [Related]
7. Impact of Baseline Anxiety on Well-being in People with Post-COVID-19 Condition: A Secondary Analysis.
Kleine N; Kwan ATH; Le GH; Guo Z; Phan L; Subramaniapillai M; McIntyre RS
CNS Spectr; 2024 Apr; 29(2):150-154. PubMed ID: 38453677
[TBL] [Abstract][Full Text] [Related]
8. Greater Role of Cognitive Impairment Over Fatigue in Post-COVID-19 Quality of Life: A Post-Hoc Analysis of a Randomized Controlled Trial.
Kwan ATH; Lakhani M; Le GH; Singh G; Teopiz KM; Guo Z; Ceban F; Dhaliwal KK; Badulescu S; Ho R; Rhee TG; Cao B; d'Andrea G; McIntyre RS
medRxiv; 2024 Mar; ():. PubMed ID: 38562760
[TBL] [Abstract][Full Text] [Related]
9. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.
Chokka P; Bougie J; Proulx J; Tvistholm AH; Ettrup A
CNS Spectr; 2019 Dec; 24(6):616-627. PubMed ID: 30802419
[TBL] [Abstract][Full Text] [Related]
10. Impact of Elevated Body Mass Index (BMI) on Hedonic Tone in Persons with Post-COVID-19 Condition: A Secondary Analysis.
Le GH; Kwan ATH; Wong S; Guo Z; Teopiz KM; Badulescu S; Meshkat S; d'Andrea G; Ho R; Rhee TG; Cao B; Phan L; Rosenblat JD; Mansur RB; Subramaniapillai M; McIntyre RS
Adv Ther; 2024 Feb; 41(2):686-695. PubMed ID: 38114867
[TBL] [Abstract][Full Text] [Related]
11. The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder.
Cao B; Park C; Subramaniapillai M; Lee Y; Iacobucci M; Mansur RB; Zuckerman H; Phan L; McIntyre RS
Front Psychiatry; 2019; 10():17. PubMed ID: 30766492
[No Abstract] [Full Text] [Related]
12. The effect of vortioxetine on overall patient functioning in patients with major depressive disorder.
Florea I; Loft H; Danchenko N; Rive B; Brignone M; Merikle E; Jacobsen PL; Sheehan DV
Brain Behav; 2017 Mar; 7(3):e00622. PubMed ID: 28293465
[TBL] [Abstract][Full Text] [Related]
13. Impacts of metabolic disruption, body mass index and inflammation on cognitive function in post-COVID-19 condition: a randomized controlled trial on vortioxetine.
Kwan ATH; Le GH; Guo Z; Ceban F; Teopiz KM; Rhee TG; Ho R; Di Vincenzo JD; Badulescu S; Meshkat S; Cao B; Rosenblat JD; Dev DA; Phan L; Subramaniapillai M; McIntyre RS
Ann Gen Psychiatry; 2024 Feb; 23(1):10. PubMed ID: 38424537
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder.
McIntyre RS; Loft H; Christensen MC
Neuropsychiatr Dis Treat; 2021; 17():575-585. PubMed ID: 33654400
[TBL] [Abstract][Full Text] [Related]
15. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram.
Levada OA; Troyan AS
J Affect Disord; 2019 May; 250():114-122. PubMed ID: 30852363
[TBL] [Abstract][Full Text] [Related]
16. Impact of elevated body mass index (BMI) on cognitive functioning and inflammation in persons with post-COVID-19 condition: a secondary analysis.
Le GH; Kwan ATH; Guo Z; Wong S; Badulescu S; Gill H; Teopiz KM; Meshkat S; Ceban F; Phan L; Subramaniapillai M; Di Vincenzo JD; Rosenblat JD; Mansur RB; d'Andrea G; Ho R; Rhee TG; McIntyre RS
Acta Neuropsychiatr; 2024 Apr; ():1-7. PubMed ID: 38605630
[TBL] [Abstract][Full Text] [Related]
17. Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects.
Papalexi E; Galanopoulos A; Kontis D; Markopoulou M; Balta G; Karavelas E; Panagiotidis P; Vlachos T; Ettrup A
BMC Psychiatry; 2022 Aug; 22(1):548. PubMed ID: 35962369
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of vortioxetine in working patients with generalized anxiety disorder.
Christensen MC; Loft H; Florea I; McIntyre RS
CNS Spectr; 2019 Apr; 24(2):249-257. PubMed ID: 29081307
[TBL] [Abstract][Full Text] [Related]
19. Vortioxetine for depression in adults.
Koesters M; Ostuzzi G; Guaiana G; Breilmann J; Barbui C
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011520. PubMed ID: 28677828
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma.
Christensen MC; Florea I; Loft H; McIntyre RS
J Affect Disord; 2020 Feb; 263():258-266. PubMed ID: 31818787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
